Select publications

Publications discussed by Dr Perez

Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract

Osborne CK et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002;20(16):3386-95. Abstract

O'Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002 Jun 15;20(12):2812-23. Abstract

Perey L et al. Fulvestrant ('Faslodex') as hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitors. Breast Cancer Res Treat 2002; Abstract 249.

Perez EA et al. A Phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 2000 1;88(1):124-31. Abstract

Perez EA et al. Randomized Phase II study of 2 schedules of irinotecan (CPT-11) for patients (pts) with refractory metastatic breast cancer (MBC): An NCCTG Cooperative Group study. Proc Am Soc Clin Oncol 2002. Abstract 206.

Robert N et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer. Breast Cancer Res Treat 2002;Abstract 35.

Sledge GW et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An Intergroup trial (E1193). J Clin Oncol 2002;21(4):588-92. Abstract

Epidermal growth factor receptor (EGFR) inhibitors in breast cancer

Arteaga CL et al. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Oncol 2002;29(3 Suppl 11):4-10. Abstract

Kim TE, Murren JR. Erlotinib OSI/Roche/Genentech. Curr Opin Investig Drugs 2002;3(9):1385-95. Abstract

Moasser MM et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001 Oct 1;61(19):7184-8. Abstract

Morris C. The role of EGFR-directed therapy in the treatment of breast cancer. Breast Cancer Res Treat 2002;75 (Suppl 1):S51-5; discussion S57-9. Abstract

Moulder SL et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61(24):8887-95. Abstract

Nicholson RI et al. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen receptor-positive breast cancer. Ann N Y Acad Sci 2002;963:104-15. Abstract

Normanno N et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002;13(1):65-72. Abstract

Normanno N et al. Target-based agents against ErbB receptors and their ligands: A novel approach to cancer treatment. Endocr Relat Cancer 2003;10(1):1-21. Abstract

Ranson M. ZD1839 (Iressa): For more than just non-small cell lung cancer. Oncologist 2002;7 (Suppl 4):16-24. Abstract

Slichenmyer WJ, Fry DW. Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin Oncol 2001;28(5 Suppl 16):67-79. Abstract

Platinum-taxane regimens in breast cancer

Brufsky AM et al. A Phase II study of carboplatin and docetaxel as first-line chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 2002. Abstract 2020.

Hurley J et al. Neoadjuvant Herceptin/taxotere/cisplatin in the treatment of locally advanced and inflammatory breast cancer. Proc Am Soc Clin Oncol 2002. Abstract 196.

Kallab AM et al. A Phase II study of weekly paclitaxel and carboplatin in metastatic breast cancer. Proc Am Soc Clin Oncol 2002. Abstract 1953.

Taki T et al. Treatment of patients with CAF resistant relapsed breast cancer with docetaxel and cisplatin. Proc Am Soc Clin Oncol 2002. Abstract 1985.

Yardley DA et al. Final results of the Minnie Pearl Cancer Research Network first-line trial of weekly paclitaxel/carboplatin/trastuzumab in metastatic breast cancer. Breast Cancer Res Treat 2002; Abstract 439.

Crown JP. The platinum agents: A role in breast cancer treatment? Semin Oncol 2001;28(1 Suppl 3):28- 37. Abstract

Crown J. Nonanthracycline containing docetaxel-based combinations in metastatic breast cancer. Oncologist 2001;6 Suppl 3:17-21. Abstract

Ezzat AA et al. High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin. Breast Cancer Res Treat 2000;62(3):237-44. Abstract

Kariya S et al. Docetaxel-cisplatin combined chemotherapy in Japanese patients with anthracyclinepretreated advanced breast cancer. Oncol Rep 2002;9(6):1345-9. Abstract

Loesch D et al. Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J Clin Oncol 2002;20(18):3857-64. Abstract

Mavroudis D et al. Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial. Oncology 2003;64(3):207-12. Abstract

Rosati G et al. A phase II study of paclitaxel/cisplatin combination in patients with metastatic breast cancer refractory to anthracycline-based chemotherapy. Tumori 2000;86(3):207-10. Abstract

Home · Search